Therapeutic Targeting of mTORC2 in mTORopathies

Brianne Dentel, Christine Ochoa Escamilla, Peter T. Tsai

Research output: Contribution to journalArticle

Abstract

Dysregulated mTOR contributes to neurodevelopmental dysfunction. A new study (Chen et al., 2019) demonstrates that suppression of mTORC2, not mTORC1, ameliorates survival, seizures, and abnormal behaviors in a Pten mutant model, highlighting mTORC2 as a potential therapeutic target in mTORopathies. Dysregulated mTOR contributes to neurodevelopmental dysfunction. A new study (Chen et al., 2019) demonstrates that suppression of mTORC2, not mTORC1, ameliorates survival, seizures, and abnormal behaviors in a Pten mutant model, highlighting mTORC2 as a potential therapeutic target in mTORopathies.

Original languageEnglish (US)
Pages (from-to)1032-1033
Number of pages2
JournalNeuron
Volume104
Issue number6
DOIs
StatePublished - Dec 18 2019

ASJC Scopus subject areas

  • Neuroscience(all)

Fingerprint Dive into the research topics of 'Therapeutic Targeting of mTORC2 in mTORopathies'. Together they form a unique fingerprint.

  • Cite this